India, Oct. 11 -- Chronic disease management firm Wellthy Therapeutics on Friday said it has partnered with German life sciences group Bayer G4A to improve its product, regulatory and commercialisation capabilities and explore areas of collaboration.
As part of the partnership, G4A team will work closely with Wellthy Therapeutics to improve its capabilities while exploring areas of collaboration, Wellthy Therapeutics said in a statement.
"We look forward to supporting the advancement of their patient centric, outcomes focused approach to care, and explore opportunities to collaborate," Bayer G4A Digital Health Global Head Eugene Borukhovich said.
Advancements in digital therapeutics over the last few years have been enabling an integrate...